CELSION CORP (CLSN) Stock Price, Quote, News and Overview
NASDAQ:CLSN - Nasdaq - US15117N6022 - Common Stock - Currency: USD
CLSN Quote, Performance and Key Statistics
1.96
0 (0%)
The current stock price of CLSN is 1.96 USD. In the past month the price decreased by -15.52%. In the past year, price decreased by -87.06%.
CLSN Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About CLSN
Company Profile
Celsion Corp .is a clinical stage oncology drug company. The company is headquartered in Lawrence Township, New Jersey and currently employs 29 full-time employees. The firm is focused on advancing a portfolio of treatments, including deoxyribonucleic acid (DNA)-based immunotherapies, vaccines and directed chemotherapies through clinical trials and eventual commercialization. The firm's product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, its heat-activated liposomal encapsulation of doxorubicin, under investigator-sponsored development for several cancer indications. The company has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies and vaccines, and other anti-cancer DNA or ribonucleic acid (RNA) therapies. Both are synthetic, non-viral vectors with capability in nucleic acid cellular transfection. Its TheraPlas is a technology platform for the delivery of DNA and messenger RNA (mRNA) therapeutics via synthetic non-viral carriers.
Company Info
CELSION CORP
997 Lenox Dr Ste 100
Lawrence Township NEW JERSEY 08648 US
CEO: Michael H. Tardugno
Employees: 29
Company Website: http://celsion.com/
Phone: 16098969100.0
CELSION CORP / CLSN FAQ
What is the stock price of CELSION CORP today?
The current stock price of CLSN is 1.96 USD.
What is the ticker symbol for CELSION CORP stock?
The exchange symbol of CELSION CORP is CLSN and it is listed on the Nasdaq exchange.
On which exchange is CLSN stock listed?
CLSN stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CELSION CORP stock?
8 analysts have analysed CLSN and the average price target is 27.54 USD. This implies a price increase of 1305.1% is expected in the next year compared to the current price of 1.96. Check the CELSION CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CELSION CORP worth?
CELSION CORP (CLSN) has a market capitalization of 13.91M USD. This makes CLSN a Nano Cap stock.
How many employees does CELSION CORP have?
CELSION CORP (CLSN) currently has 29 employees.
What are the support and resistance levels for CELSION CORP (CLSN) stock?
CELSION CORP (CLSN) has a support level at 1.95 and a resistance level at 1.98. Check the full technical report for a detailed analysis of CLSN support and resistance levels.
Should I buy CELSION CORP (CLSN) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CLSN, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CLSN, evaluating the profitability, health, valuation and growth aspects
- CELSION CORP (CLSN) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CELSION CORP (CLSN) Sales and EPS estimates to see what analysts future expectations are.
- CELSION CORP (CLSN) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CELSION CORP (CLSN) Insider and Institutional Ownership to learn about the owners and their transactions.
- CELSION CORP (CLSN) Stock Chart to make your own analysis
- CELSION CORP (CLSN) Latest news and press-releases to stay up to date.
Does CELSION CORP (CLSN) stock pay dividends?
CLSN does not pay a dividend.
When does CELSION CORP (CLSN) report earnings?
CELSION CORP (CLSN) will report earnings on 2022-11-14.
What is the Price/Earnings (PE) ratio of CELSION CORP (CLSN)?
CELSION CORP (CLSN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-7.21).
CLSN Technical Analysis
CLSN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CLSN. Both the profitability and financial health of CLSN have multiple concerns.
CLSN Financial Highlights
Over the last trailing twelve months CLSN reported a non-GAAP Earnings per Share(EPS) of -7.21. The EPS decreased by -35.02% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -5229.82% | ||
| ROA | -40.03% | ||
| ROE | N/A | ||
| Debt/Equity | 0.13 |
CLSN Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to CLSN. The Buy consensus is the average rating of analysts ratings from 8 analysts.